Trustees’ Annual Report for the period
From 01 January 2025 Period start date To 31 December 2025 Period end date
Charity name: Foundation for Angelman Syndrome Therapeutics UK Charity registration number: 1167984
Objectives and Activities
| SORP reference | ||
|---|---|---|
| Summary of the purposes of the charity as set out in its governing document |
Para 1.17 | The objects of the CIO are:- 1. the advancement of health for the benefit of the public by the provision of support towards research into Angelman syndrome including their treatment and cure, and the publication of the useful results of such research; and 2. the relief of those in need of care, assistance and support as a consequence of living with Angelman Syndrome. |
| Summary of the main activities in relation to those purposes for the public benefit, in particular, the activities, projects or services identified in the accounts. |
Para 1.17 and 1.19 |
Foundation for Angelman Syndrome Therapeutics UK continues to assist Oxford University in funding a Natural History Study for Angelman Syndrome. The study has been funded by FAST UK for 4 years and has now been extended by another 2 years with the recruitment of 15 more patients. As well as this, FAST UK is funding to support the delivery of weekend lumbar puncture (LP) clinics as part of the Angelman syndrome clinical research programme at the University of Oxford. |
| Statement confirming whether the trustees have had regard to the guidance issued by the Charity Commission on public benefit |
Para 1.18 | The trustees have had regard to the guidance issued by the Charity Commission on public benefit. |
Additional information (optional) You may choose to include further statements where relevant about:
SORP reference Para 1.38 Policy on grant making Para 1.38
Policy on social investment including program related investment Para 1.38 Contribution made by volunteers Other
Achievements and Performance
| SORP reference | ||
|---|---|---|
| Summary of the main achievements of the charity, identifying the difference the charity’s work has made to the circumstances of its beneficiaries and any wider benefits to society as a whole. |
Para 1.20 | Fund raising activities and donations through-out the financial period have raised income of £29,329. FAST UK is linked with FAST US who are making huge steps into finding a cure for Angelman Syndrome through scientific research, and FAST UK have continued to support FAST US’s efforts with this. FAST UK has committed to fund the Natural History Study in conjunction with Oxford University for another 5 years with an additional year for data analysis. Funding of £25,732 per year will be provided in the years 2026 to 2031 inclusive. FAST UK have also committed to funding an AS weekend lumbar puncture clinic to ensure trials are kept on track and in timelines at a cost of £108,000 over 3 years with a start date of June 2026. The NHS continues to be a success with useful and meaningful data. Clinical trials are also currently taking place in Oxford with more pharma companies looking to start their trials next year. |
Additional information (optional) You may choose to include further statements where relevant about:
Achievements against Para 1.41 objectives set
| Performance of fundraising activities against objectives set |
Para 1.41 | |
|---|---|---|
| Investment performance against objectives |
Para 1.41 | |
| Other |
Financial Review
| Financial Review | ||
|---|---|---|
| Review of the charity’s financial position at the end of the period |
Para 1.21 | At the end of the period the charity was in a net asset position of £347,206. |
| Statement explaining the policy for holding reserves stating why they are held |
Para 1.22 | There is no reserves policy, and no reserves are held. |
| Amount of reserves held | Para 1.22 | Nil. Cash at year end was £347,206, none of which is specifically held in reserves. |
| Reasons for holding zero reserves |
Para 1.22 | The charity is small, with one employee and has minimal fixed costs or expenses, and is in a positive cash position and as such no reserves are required. |
| Details of fund materially in deficit |
Para 1.24 | N/A |
| Explanation of any uncertainties about the charity continuing as a going concern |
Para 1.23 | There are no uncertainties over the charity’s ability to continue as a going concern. There are substantial cash reserves to support the on-going level of expenditure. |
Additional information (optional) You may choose to include further statements where relevant about: The charity’s principal sources of funds (including Para 1.47 any fundraising) Investment policy and objectives including any Para 1.46 social investment policy adopted A description of the principal Para 1.46 risks facing the charity Other
Structure, Governance and Management
| Description of charity’s trusts: |
||
|---|---|---|
| Type of governing document (trust deed, royal charter) |
Para 1.25 | Constitution |
| How is the charity constituted? (e.g unincorporated association, CIO) |
Para 1.25 | A Charitable Incorporated Organisation |
| Trustee selection methods including details of any constitutional provisions e.g. election to post or name of any person or body entitled to appoint one or more trustees |
Para 1.25 | Apart from the first charity trustees, every trustee must be appointed by a resolution passed at a properly convened meeting of the charity trustees. |
Additional information (optional) You may choose to include further statements where relevant about:
| Policies and procedures adopted for the induction and training of trustees |
Para 1.51 | |
| The charity’s organisational structure and any wider network with which the charity works |
Para 1.51 | |
| Relationship with any related parties |
Para 1.51 | |
| Other |
Reference and Administrative details
| Charity name | Foundation for Angelman Syndrome Therapeutics UK |
|---|---|
| Other name the charity uses | FAST UK |
| Registered charity number | 1167984 |
| Charity’s principal address | 13 Inglethorpe Street, London, SW6 6NS |
Names of the charity trustees who manage the charity
| 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 |
Trustee name | Office (if any) | Dates acted if not for whole year |
Nam e of pers on (or body ) entitl ed to appo int trust ee (if any) |
|---|---|---|---|---|
| Thomas Keogh | Chair | |||
| Tamsin Keogh | ||||
| Antonia Felix | ||||
| Louise Prince | ||||
| Katharine Hamilton | ||||
| Julien de Bournet | ||||
| Sarah Washbrook | 16/06/2016 -present | |||
| 20 |
– Corporate trustees names of the directors at the date the report was approved
Director name
Name of trustees holding title to property belonging to the charity
Trustee name Dates acted if not for whole year
Funds held as custodian trustees on behalf of others
| Description of the assets held in this capacity |
N/A |
|---|---|
| Name and objects of the charity on whose behalf the assets are held and how this falls within the custodian charity’s objects |
N/A |
| Details of arrangements for safe custody and segregation of such assets from the charity’s own assets |
N/A |
Additional information (optional)
Names and addresses of advisers (Optional information)
| Type of adviser Name Address |
Type of adviser Name Address |
Type of adviser Name Address |
|
|---|---|---|---|
| Name of chief executive or names of senior staff members (Optional information) | |||
Declarations
The trustees declare that they have approved the trustees’ report above.
Signed on behalf of the charity’s trustees Signature(s) Full name(s) Thomas Keogh Position (eg Chair Secretary, Chair, etc) Date 26/10/2026
Charity Name No (if any) Foundation for Angelman Syndrome Therapeutics UK 1167984 Receipts and payments accounts CC16a For the period Period start date Period end date To from 01-Jan-25 31-Dec-25
| Section A Receipts and payments | Section A Receipts and payments | |||||
|---|---|---|---|---|---|---|
| A1 Receipts | Unrestricted funds to the nearest £ 29,329 - - - - - - - 29,329 - - - 29,329 4,182 562 442 1,000 10,437 125 - - - 16,748 - - - 16,748 12,581 - 334,625 347,206 |
Restricted funds to the nearest £ - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - |
Endowment funds to the nearest £ - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - |
Total funds to the nearest £ 29,329 - - - - - - - 29,329 - - - 29,329 4,182 562 442 1,000 10,437 125 - - - 16,748 - - - 16,748 12,581 |
Last year to the nearest £ |
|
| Fundraisingand Donations | 29,329 | 183,082 | ||||
| - | - | |||||
| - | - | |||||
| - | - | |||||
| - | - | |||||
| - | - | |||||
| - | - | |||||
| - | - | |||||
| Sub total(Gross income for AR) |
29,329 | 183,082 | ||||
| A2 Asset and investment sales, (see table). |
||||||
| - | ||||||
| - | - | |||||
| ~~Sub total~~ | - | - | ||||
| Total receipts A3 Payments |
||||||
| 183,082 | ||||||
| Salary,Pension and Related Expenses | 4,182 | 10,151 | ||||
| Incurred raisingdonations | 562 | 562 | ||||
| Marketing,Advertisingand Postage | 442 | 1,106 | ||||
| Website Cost | 1,000 | 1,000 | ||||
| StagingFundraisingevents | 10,437 | 25,008 | ||||
| Subscriptions and Memberships | 125 | - | ||||
| - | - | |||||
| - | - | |||||
| - | - | |||||
| **Sub total ** | 16,748 | 37,827 | ||||
| A4 Asset and investment purchases, (see table) |
||||||
| - | ||||||
| - | ||||||
| **Sub total ** | - | - | ||||
| Total payments Net of receipts/(payments) A5 Transfers between funds A6 Cash funds last year end Cash funds this year end |
||||||
| 37,827 | ||||||
| 12,581 | - | - | 12,581 | 145,255 | ||
| - | - | - | - | - | ||
| 334,625 | - | - | 334,625 | 189,370 | ||
| 347,206 | - | - | 347,206 | 334,625 |
CCXX R1 accounts (SS)
13/10/2026
1
| Section B Statement of assets and liabilities at the end of the period | Section B Statement of assets and liabilities at the end of the period | Section B Statement of assets and liabilities at the end of the period | |
|---|---|---|---|
| Categories Signed by one or two trustees on behalf of all the trustees B5 Liabilities B3 Investment assets B2 Other monetary assets B4 Assets retained for the charity’s own use B1 Cash funds |
Details Details Total cash funds (agree balances with receipts and payments account(s)) Cash at Bank Details Details Details Signature |
Unrestricted funds Restricted funds to nearest £ to nearest £ 347,206 - - - - - 347,206 - OK OK Unrestricted funds Restricted funds to nearest £ to nearest £ - - - - - - - - - - - - Fund to which asset belongs Cost (optional) - - - - - Fund to which asset belongs Cost (optional) - - - - - - - - - Fund to which liability relates Amount due (optional) - - - - - Print Name Tom Keogh Katharine Hamilton |
Endowment funds to nearest £ |
| - | |||
| - | |||
| - | |||
| - | |||
| OK | |||
| Endowment funds to nearest £ |
|||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| Current value (optional) |
|||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| Current value (optional) |
|||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| When due (optional) |
|||
| Date of approval |
|||
| Tom Keogh | 12/10/2026 | ||
| Katharine Hamilton | 12/10/2026 |
CCXX R2 accounts (SS)
13/10/2026
2
CHARITY COMM15510NI •wnln•f• FOR ENGIAND APIO WAIES qr